Buprenorphine
When ATH:
N02AE01
Characteristic.
The white crystalline powder. It is soluble in water, soluble in alcohol.
Pharmacological action.
Analgesic (opioid).
Application.
Painful high intensity syndrome (after surgery, in cancer patients, myocardial infarction, počečnaâ how, burns).
Contraindications.
Hypersensitivity, physical dependence.
Restrictions apply.
Respiratory and renal failure, traumatic brain injury, pregnancy, lactation.
Pregnancy and breast-feeding.
Category actions result in FDA - C. (The study of reproduction in animals has revealed adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not held, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk.)
Side effects.
Headache, dizziness, Sweating, dry mouth, nausea, vomiting.
Cooperation.
Strengthens (mutually) the main and side effects, as well as the toxicity of MAO inhibitors and funds, CNS depressants (trankvilizatorov, neuroleptics and others.).
Overdose.
Manifested depression of the respiratory center.
Treatment: vvodyat naloxone, and symptomatic agents.
Dosing and Administration.
B /, / m, sublingually. Single dose for adults with in / and the / m - 0.3-0.45 mg. If necessary, the injection was repeated every 6-8 hours.
With sublingual - 0.2-0.4 mg every 6-8 hours between the intake of.
Cooperation
| Active substance | Description of interaction |
| Acrivastine | FMR: synergism. Strengthens (mutually) CNS depression. |
| Alprazolam | FMR: synergism. Strengthens (mutually) CNS depression. |
| Buspirone | FMR: synergism. Strengthens (mutually) CNS depression. |
| Haloperidol | FMR: synergism. Strengthens (mutually) CNS depression. |
| Gidroksizin | FMR: synergism. Strengthens (mutually) CNS depression. |
| Diazepam | FMR: synergism. Strengthens (mutually) CNS depression; simultaneous use can cause respiratory and / or cardiovascular collapse. |
| Difengidramin | FMR: synergism. Strengthens (mutually) CNS depression. |
| Droperidol | FMR: synergism. Strengthens (mutually) CNS depression. |
| Zolpidem | FMR: synergism. Strengthens (mutually) CNS depression. |
| Izofluran | FMR: synergism. Strengthens (mutually) CNS depression. |
| Carbamazepine | FKV. As inducers of CYP3A4 may accelerate the clearance and increase the biotransformation of. |
| Quetiapine | FMR: synergism. Strengthens (mutually) CNS depression. |
| Ketamine | FMR: synergism. Strengthens (mutually) CNS depression. |
| Ketoconazole | FKV. As an inhibitor of CYP3A4 slows down and reduces the clearance of biotransformation. |
| Clemastine | FMR: synergism. Strengthens (mutually) CNS depression. |
| Klozapyn | FMR: synergism. Strengthens (mutually) CNS depression. |
| Clonazepam | FMR: synergism. Strengthens (mutually) CNS depression. |
| Codeine | FMR: synergism. Strengthens (mutually) CNS depression; combined use does not make sense. |
| Lorazepam | FMR: synergism. Strengthens (mutually) CNS depression. |
| Loratadine | FMR: synergism. Strengthens (mutually) CNS depression. |
| Metoclopramide | FMR. Sedative effect. Against the background of buprenorphine is attenuated stimulation of motor activity gastrointestinal tract. |
| Midazolam | FMR: synergism. Strengthens (mutually) CNS depression. |
| Morphine sulfate | FMR: synergism. Strengthens (mutually) CNS depression; combined use does not make sense. |
| Oxazepam | FMR: synergism. Strengthens (mutually) CNS depression. |
| Olanzapine | FMR: synergism. Strengthens (mutually) CNS depression. |
| Perfenazyn | FMR: synergism. Strengthens (mutually) CNS depression. |
| Pramipexole | FMR: synergism. Sedative effect; In sharing caution. |
| Promethazine | FMR: synergism. Strengthens (mutually) CNS depression. |
| Propofol | FMR: synergism. Strengthens (mutually) CNS depression. |
| Ritonavir | FKV. As an inhibitor of CYP3A4 may slow biotransformation and reduce clearance. |
| Rifampicin | FKV. As inducers of CYP3A4 may increase the clearance. |
| Selegiline | FMR. Concomitant use is contraindicated: stupor may develop, muscle rigidity, ažitacii, gallyutsinatsii, giperpireksii, and respiratory distress, coma, convulsions and death. |
| Tioridazin | FMR: synergism. Strengthens (mutually) CNS depression. |
| Topiramate | FMR: synergism. Strengthens (mutually) CNS depression. |
| Trifluoperazine | FMR: synergism. Strengthens (mutually) CNS depression. |
| Fexofenadine | FMR: synergism. Strengthens (mutually) CNS depression. |
| Phenytoin | FKV. As inducers of CYP3A4 may accelerate the clearance and increase the biotransformation of. |
| Phenobarbital | FMR: synergism. Strengthens (mutually) CNS depression. |
| Fentanyl | FMR: synergism. Strengthens (mutually) CNS depression; combined use does not make sense. |
| Flufenazin | FMR: synergism. Strengthens (mutually) CNS depression. |
| Xlordiazepoksid | FMR: synergism. Strengthens (mutually) CNS depression. |
| Chlorpromazine | FMR: synergism. Strengthens (mutually) CNS depression. |
| Chlorprothixene | FMR: synergism. Strengthens (mutually) CNS depression. |
| Cetirizine | FMR: synergism. Strengthens (mutually) CNS depression. |
| Ciprogeptadin | FMR: synergism. Strengthens (mutually) CNS depression. |
| Erythromycin | FKV. As an inhibitor of CYP3A4 reduced clearance. |
| Ethanol | FMR: synergism. Strengthens (mutually) CNS depression; at the time of treatment should abandon spirits. |
